|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
|
|---|---|---|---|---|
| ASSETS | ||||
| CURRENT ASSETS | ||||
| Cash and cash equivalents | ||||
| Inventory, net | ||||
| Prepaid expenses and other current assets | ||||
| TOTAL CURRENT ASSETS | ||||
| Intellectual property, net, a related party | ||||
| Investment in NovoDX, a related party | ||||
| TOTAL ASSETS | ||||
| LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||
| CURRENT LIABILITIES | ||||
| Accounts payable | ||||
| Related party loan payable | ||||
| Accrued expenses and other current liabilities | ||||
| TOTAL CURRENT LIABILITIES | ||||
| NON CURRENT LIABILITIES | ||||
| Long-term debt, net | ||||
| TOTAL NON CURRENT LIABILITIES | ||||
| TOTAL LIABILITIES | ||||
| MEZZANINE EQUITY | ||||
| Series A Convertible Redeemable preferred stock, $0.001 par value, 4,500 shares and 0 shares authorized as of June 30, 2026 and December 31, 2025, respectively, 4,233 shares and 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||
| TOTAL MEZZANINE EQUITY | ||||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||||
| Common stock, par value of $0.001 per share; 100,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 9,091,506, and 14,761,925 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively * | ||||
| Additional paid-in capital | ||||
| Common stock payable | ||||
| Subscription receivable | ||||
| Receivable from related party for stock repurchase | ||||
| Accumulated deficit | ||||
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | ||||
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) |
Loading...
